Sun Pharmaceutical Industries Ltd.
NSE: SUNPHARMASun Pharmaceutical Industries Ltd.: A 30-second snapshot
Sun Pharma trades at Rs 1,945, up 20.26% over the past year and 6.87% over three months, sitting 4.98% below its 52-week high and above both its 50-day (1,885.96) and 200-day (1,775.23) moving averages, with RSI at a neutral 52.1. Q1 FY27 profit rose 27% year-over-year to Rs 2,894 crore on 10.5% revenue growth, alongside continued progress on the proposed Organon merger, which cleared Organon shareholder approval on July 24, 2026. Trailing PE is 38.6x (forward 29.6x) against a Pharma peer set spanning 29.5x (Dr. Reddy's) to 85.5x (Divi's Labs).
P/E
38.6
Forward P/E
29.6
ROE
—
Debt / Equity
5.52
Profit Margin
+20.2%
Div. Yield
+0.8%
5Y ROE > 15%
3/5
5Y FCF > 0
4/5
Quality
73/100
News
8 headlines · 7 positive · 1 negative
Sun Pharma's quarterly profit jumps on strength in specialty medicines - Reuters
Reuters
Sun Pharma Q1 net profit rises 27 percent to Rs 2,894 crore, misses estimates; revenue also below poll - Moneycontrol.com
Moneycontrol.com
Sun Pharma Q1 Results: Profit rises 27% YoY to Rs 2,895 crore; revenue climbs 10.5% - economictimes.com
economictimes.com
Organon shareholders approve merger with Sun Pharma - Fortune India
Fortune India
Sun Pharma gets nod from South African regulator for generic semaglutide injection - The Hindu
The Hindu
Recent context
- ·Q1 FY27 results (July 31, 2026): net profit up 27% year-over-year to Rs 2,894 crore on 10.5% revenue growth, reported positively by Reuters and Economic Times, with Moneycontrol noting the print came in below revenue and profit estimates.
- ·Organon shareholders approved the proposed merger with Sun Pharma on July 24, 2026, per Fortune India; available data covers this shareholder vote only.
- ·Sun Pharma received South African regulatory approval for a generic semaglutide injection, reported July 15, 2026 (The Hindu).
Strengths
- +Price sits above both the 50-day (1,885.96) and 200-day (1,775.23) simple moving averages, up 20.26% over 12 months and 6.87% over 3 months, only 4.98% below its 52-week high.
- +Q1 FY27 net profit rose 27% year-over-year to Rs 2,894 crore, with a 20.19% profit margin and 10.5% revenue growth.
- +Free cash flow was positive in 4 of the tracked years, debt trend is described as falling, and the quality score of 57 ranks 1st of 6 among the Pharma peers tracked.
- +Mean analyst rating of 1.76 across 33 analysts (1-5 scale, lower = more constructive); 7 of the 8 most recent news items carry positive sentiment.
Weaknesses
- −Current-period ROE is not reported; only 3 of the tracked years show ROE above 15% (consistency score 73/100), a softer read than the 27.4% five-year earnings growth alone would suggest.
- −A Moneycontrol report on the July 31, 2026 Q1 print described revenue and profit as coming in below analyst estimates, even as the same quarter's 27% year-over-year profit growth was reported positively elsewhere.
- −The proposed Organon merger cleared shareholder approval on July 24, 2026, but deal financing structure, closing timeline and integration detail are not present in the available data.
- −Trailing PE of 38.6x sits above 3 of the 5 tracked Pharma peers (Dr. Reddy's 29.5x, Cipla 35.1x, Apollo Hospitals 66.2x), though below Max Healthcare (72.4x) and Divi's Labs (85.5x).
Open questions
- ?What are the disclosed financing terms and expected closing timeline for the Organon merger, and how might they affect the currently falling debt-to-equity trend?
- ?Does the gap between ROE above 15% in only 3 of the tracked years and 27.4% five-year earnings growth reflect margin-driven earnings without a matching improvement in capital efficiency?
- ?How do the estimate-beat framing (27% profit growth) and the estimate-miss framing reported by Moneycontrol reconcile on a line-by-line basis for the same Q1 FY27 print?
- ?Where does the current trailing PE of 38.6x sit relative to Sun Pharma's own 5-year PE history, beyond the cross-sectional comparison against Pharma peers?
Peer comparison: Pharma
Ranks 1 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries Ltd.You're viewing | 38.6 | — | 57 |
| Industry avg | across 5 peers | 57.7 | +14.9% | 34 |
| DIVISLAB | Divi's Laboratories Ltd. | 85.5 | — | 57 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 66.2 | +21.5% | 44 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 72.4 | +14.3% | 37 |
| CIPLA | Cipla Ltd. | 35.1 | — | 28 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 29.5 | +8.8% | 4 |
Technical state
Current price
₹1,945.00
SMA 50
₹1,885.96
SMA 200
₹1,775.23
RSI (14)
52.1 (neutral)
From 52w high
-5.0%
1Y return
+20.3%
3M return
+6.9%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- lowCurrent-period ROE is not reported (null) in the fundamentals data; only historical persistence metrics are available (ROE above 15% in 3 of the tracked years, consistency score 73/100). Sector-peer ROE and 1-year price-change figures are also null for most of the 5 tracked Pharma peers, limiting cross-sectional comparison.
- mediumQ1 FY27 results (reported July 31, 2026) showed net profit up 27% year-over-year to Rs 2,894 crore on 10.5% revenue growth, covered positively by Reuters and Economic Times, while a Moneycontrol report on the same print characterized both revenue and profit as coming in below analyst estimates.
- mediumA proposed merger between Sun Pharma and Organon cleared an Organon shareholder-approval milestone on July 24, 2026 (Fortune India). The available data covers the shareholder vote only; deal financing structure, closing timeline and integration detail are not present.
Cross-section contradictions
- 5-year earnings growth of 27.4% reflects sustained compounding, yet ROE exceeded 15% in only 3 of the tracked years (consistency score 73/100) and current-period ROE is unavailable -- earnings expansion has not been matched by an equally persistent return on the equity base in the historical record.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 11 Aug 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 8 Aug 2026 · rotates through NIFTY 500 every ~5 days